AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

AbbVie raised its fiscal 2025 adjusted earnings from $11.67-$11.87 per share to $11.88-$12.08 compared to the analysts’ estimate of $12.24.

Also Read: Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: ‘If You Refuse To Step Up We Will…’

“While management indicated that they expect some moderation in net pricing in the second half, the volume growth we are seeing from these products gives us ...